Literature DB >> 32107539

Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder.

Christopher Melani1, Elaine S Jaffe2, Wyndham H Wilson1.   

Abstract

Lymphomatoid granulomatosis (LYG) is a rare Epstein-Barr virus (EBV)-driven B-cell lymphoproliferative disease (LPD). This disease is hypothesized to result from defective immune surveillance of EBV, with most patients showing evidence of immune dysfunction, despite no known primary immunodeficiency. Pathologically, LYG is graded by the number and density of EBV+ atypical B cells, and other characteristic findings include an angioinvasive/angiodestructive reactive T-cell infiltrate and various degrees of necrosis. Clinically, LYG universally involves the lungs with other common extranodal sites, including skin, central nervous system, liver, and kidneys. Nodal and/or bone marrow involvement is extremely rare and, if present, suggests an alternative diagnosis. Treatment selection is based on histologic grade and underlying pathobiology with low-grade disease hypothesized to be immune-dependent and typically polyclonal and high-grade disease to be immune-independent and typically oligoclonal or monoclonal. Methods of augmenting the immune response to EBV in low-grade LYG include treatment with interferon-α2b, whereas high-grade disease requires immunochemotherapy. Given the underlying defective immune surveillance of EBV, patients with high-grade disease may have a recurrence in the form of low-grade disease after immunochemotherapy, and those with low-grade disease may progress to high-grade disease after immune modulation, which can be effectively managed with crossover treatment. In patients with primary refractory disease or in those with multiple relapses, hematopoietic stem cell transplantation may be considered, but its efficacy is not well established. This review discusses the pathogenesis of LYG and highlights distinct histopathologic and clinical features that distinguish this disorder from other EBV+ B-cell LPDs and lymphomas. Treatment options, including immune modulation and combination immunochemotherapy, are discussed.

Entities:  

Mesh:

Year:  2020        PMID: 32107539      PMCID: PMC7162687          DOI: 10.1182/blood.2019000933

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  70 in total

1.  Failure of rituximab monotherapy in lymphomatoid granulomatosis.

Authors:  M N Polizzotto; M A Dawson; S S Opat
Journal:  Eur J Haematol       Date:  2005-08       Impact factor: 2.997

2.  Prolonged remission of refractory lymphomatoid granulomatosis after autologous hemopoietic stem cell transplantation with post-transplantation maintenance interferon.

Authors:  Anna Johnston; Luke Coyle; David Nevell
Journal:  Leuk Lymphoma       Date:  2006-02

Review 3.  Lymphomatoid granulomatosis.

Authors:  Mark Roschewski; Wyndham H Wilson
Journal:  Cancer J       Date:  2012 Sep-Oct       Impact factor: 3.360

4.  Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.

Authors:  Sarit E Assouline; Torsten Holm Nielsen; Stephen Yu; Miguel Alcaide; Lauren Chong; David MacDonald; Axel Tosikyan; Vishal Kukreti; Abbas Kezouh; Tina Petrogiannis-Haliotis; Marco Albuquerque; Daniel Fornika; Sepideh Alamouti; Remi Froment; Celia M T Greenwood; Kathleen Klein Oros; Errol Camglioglu; Ayushi Sharma; Rosa Christodoulopoulos; Caroline Rousseau; Nathalie Johnson; Michael Crump; Ryan D Morin; Koren K Mann
Journal:  Blood       Date:  2016-05-10       Impact factor: 22.113

5.  Pulmonary lymphomatoid granulomatosis in acquired immunodeficiency syndrome: lesions with Epstein-Barr virus infection.

Authors:  A K Haque; J L Myers; S D Hudnall; B B Gelman; R V Lloyd; D Payne; M Borucki
Journal:  Mod Pathol       Date:  1998-04       Impact factor: 7.842

6.  Treatment of B-cell lymphoproliferative disorders with interferon alfa and intravenous gamma globulin.

Authors:  R S Shapiro; A Chauvenet; W McGuire; A Pearson; A W Craft; P McGlave; A Filipovich
Journal:  N Engl J Med       Date:  1988-05-19       Impact factor: 91.245

7.  Pulmonary lymphomatoid granulomatosis. Evidence for a proliferation of Epstein-Barr virus infected B-lymphocytes with a prominent T-cell component and vasculitis.

Authors:  D Guinee; E Jaffe; D Kingma; N Fishback; K Wallberg; J Krishnan; G Frizzera; W Travis; M Koss
Journal:  Am J Surg Pathol       Date:  1994-08       Impact factor: 6.394

8.  Angiocentric immunoproliferative lesions: a clinicopathologic spectrum of post-thymic T-cell proliferations.

Authors:  E H Lipford; J B Margolick; D L Longo; A S Fauci; E S Jaffe
Journal:  Blood       Date:  1988-11       Impact factor: 22.113

9.  Lymphomatoid granulomatosis: a clinicopathologic study of 42 patients.

Authors:  M N Koss; L Hochholzer; J M Langloss; W D Wehunt; A A Lazarus; P W Nichols
Journal:  Pathology       Date:  1986-07       Impact factor: 5.306

10.  Lymphomatoid granulomatosis: an analysis of clinical and immunologic characteristics.

Authors:  P P Sordillo; B Epremian; B Koziner; M Lacher; P Lieberman
Journal:  Cancer       Date:  1982-05-15       Impact factor: 6.860

View more
  15 in total

Review 1.  Granulomatous Diseases of the Central Nervous System.

Authors:  Braden Dasovic; Michael J Schneck
Journal:  Curr Neurol Neurosci Rep       Date:  2022-02-09       Impact factor: 5.081

Review 2.  New concepts in EBV-associated B, T, and NK cell lymphoproliferative disorders.

Authors:  Leticia Quintanilla-Martinez; Steven H Swerdlow; Thomas Tousseyn; Carlos Barrionuevo; Shigeo Nakamura; Elaine S Jaffe
Journal:  Virchows Arch       Date:  2022-10-11       Impact factor: 4.535

3.  Lymphomatoid granulomatosis in one patient with newly diagnosed HIV infection and Kaposi's sarcoma: a case report and literature review.

Authors:  Sindy Gutiérrez; Gilberto Barranco; Ana Ramirez; Silvia Sánchez; Pamela Alatorre; Johanna Cevallos; Carmen Lome
Journal:  J Hematop       Date:  2021-03-20       Impact factor: 0.625

4.  A case of resected pulmonary lymphomatoid granulomatosis.

Authors:  Aki Fujiwara-Kuroda; Nozomu Iwashiro; Noriko Kimura
Journal:  Respir Med Case Rep       Date:  2020-12-28

5.  Chronic lymphocytic infiltration with pontine perivascular enhancement responsive to steroids (CLIPPERS) and its association with Epstein-Barr Virus (EBV)-related lymphomatoid granulomatosis: a case report.

Authors:  Yew Li Dang; Hong Kuan Kok; Penelope A McKelvie; Matthew Ligtermoet; Laura Maddy; David A Burrows; Douglas E Crompton
Journal:  BMC Neurol       Date:  2021-02-18       Impact factor: 2.474

6.  The paradigm of hematological malignant versus non-malignant manifestations, driven by primary immunodeficiencies: a complex interplay.

Authors:  C Kelaidi; V Tzotzola; S Polychronopoulou
Journal:  Fam Cancer       Date:  2021-06-15       Impact factor: 2.375

Review 7.  Systematic Review of Spinal Lymphomatoid Granulomatosis Cases.

Authors:  Naotaka Iwamoto; Kyongsong Kim; Rinko Kokubo; Toyohiko Isu; Daijiro Morimoto; Tomoko Omura; Koji Saito; Yoshinao Kikuchi; Yasunori Ota; Akira Matsuno; Akio Morita
Journal:  World Neurosurg X       Date:  2021-04-30

8.  Pulmonary lymphomatoid granulomatosis: An uncommon disease but not to be forgotten-a single centre experience.

Authors:  Pradeep Balakrishnan; Matthew Ing; Zaid Househ; Ajantha Raguparan
Journal:  Respirol Case Rep       Date:  2021-05-26

9.  A 67-Year-Old Woman With Abdominal Pain, Paresthesia, and Rapidly Expanding Lung Nodule.

Authors:  Ryan Hyde; James Wynne; Peruvemba Sriram; Li Lu; Susheela Hadigal
Journal:  Chest       Date:  2021-07       Impact factor: 10.262

10.  High-grade Primary Central Nervous System Lymphomatoid Granulomatosis: Successful Rituximab Monotherapy.

Authors:  Sakiko Harada; Jun Ando; Miki Ando; Hideaki Nitta; Tadaaki Inano; Yusuke Hirasawa; Yoshiki Furukawa; Shintaro Kinoshita; Akihide Kondo; Koichi Ohshima; Norio Komatsu
Journal:  Intern Med       Date:  2021-06-12       Impact factor: 1.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.